A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS)

被引:0
|
作者
Yao, Wanru [1 ]
Ai, Di [1 ]
Zhang, Qing [2 ]
Li, Xiaojing [3 ]
Zhou, Min [2 ]
Zhang, Ningning [4 ]
Yang, Sheng [5 ]
Chen, Zhenping [6 ]
Zhen, Yingzi [1 ]
Luke, Koon-Hung [7 ,8 ]
Wu, Runhui [1 ,9 ]
机构
[1] Capital Med Univ, Key Lab Major Dis Children,Minist Educ,Beijing Chi, Natl Ctr Childrens Hlth,Natl Key Discipline Pediat, Hematol Dept,Beijing Key Lab Pediat Hematol Oncol, Beijing, Peoples R China
[2] Univ Elect Sci & Technol China, Chengdu Womens & Childrens Cent Hosp, Sch Med, Haemophilia Diag & Treatment Ctr,Dept Hematol & On, Chengdu, Peoples R China
[3] New Century Womens & Childrens Hosp, Dept Pediat, Hemophilia Treatment Ctr, Chengdu, Peoples R China
[4] Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Radiol, Beijing, Peoples R China
[5] Univ Elect Sci & Technol China, Chengdu Womens & Childrens Cent Hosp, Sch Med, Dept Ultrasound, Chengdu, Peoples R China
[6] Capital Med Univ, Beijing Childrens Hosp, Beijing Pediat Res Inst, Hematol Dis Lab, Beijing, Peoples R China
[7] Univ Ottawa, Children Hosp Eastern Ontario, Div Hematol & Oncol, Dept Pediat,Lab Med & Pathol, Ottawa, ON, Canada
[8] Univ Ottawa, Childrens Hosp Eastern Ontario CHEO, Dept Pediat, Div Hematol & Oncol, Ottawa, ON, Canada
[9] Capital Med Univ, Beijing Childrens Hosp, Hematol Ctr, Natl Ctr Childrens Hlth, Beijing 100045, Peoples R China
关键词
Haemophilia A; Individualized prophylaxis; Bleeding; China; Haemarthrosis; ARTHROPATHY; CHILDREN; LIFE;
D O I
10.1016/j.thromres.2024.109110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The Chinese Haemophilia Individualized Prophylaxis Study (CHIPS), which was launched in 2016, reported a significant reduction in haemarthrosis over a one-year study. However, its long-term efficacy requires verification. This paper summarizes the clinical outcomes of 18 severe haemophilia A (SHA) patients who completed one year on the CHIPS and 3 more years of follow-up.<br /> Methods: Clinical follow-up was based on the CHIPS protocol (from July 2018 to July 2021). Escalation was based on index joint bleeding, and serial ultrasound (greyscale and colour Doppler) examinations of the index joints (both sides of the ankles, knees and elbows) were conducted every 6 months via a scoring system.<br /> Results: A total of 18 SHA patients completed the 3-year study. Fifteen patients dropped out due to the financial crisis during the COVID-19 pandemic in China. The median age was 5.4 (range 4.3-6.9) years. A significant reduction in haemarthrosis was achieved, with mean annual bleeding rates reduced from 18.9 f 2.8 to 1.7 f 0.4 (p < 0.001), annual joint bleeding rates from 3.1 f 0.7 to1.2 f 0.3 (p < 0.028). 5 out of 8 target joint resolved. Sixteen doses were escalated. At study exit, the heterogeneous treatment outcomes of the SHA boys were 5 at step 4 (20-25 lU/kg, every other day), 10 at step 3 (15-20 IU/kg, 3x/week), 2 at step 2 (10-15 lU/kg, 3x/week) and 1 at step 1 (10-15 lU/kg, 2x/week). The mean FVIII consumption was 2964 IU/kg/year, with savings. The quality of life improved, with Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT, Chinese Version 2.0) scores ranging from 68.8 to 78.8. There was no change in the ultrasound score.<br /> Conclusion: Our follow-up data on the 18 SHA boys after completing one year on the CHIPS verify the long-term efficacy of the CHIPS for haemarthrosis reduction, joint health preservation, improvement in the quality of life of the boys and cost savings.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Pharmacokinetic profile of children with haemophilia A receiving low-dose FVIII prophylaxis in Indonesia: A single centre experience
    Primacakti, Fitri
    Sari, Teny T.
    Gatot, Djajadiman
    Sjakti, Hikari A.
    Chozie, Novie A.
    HAEMOPHILIA, 2022, 28 (05) : 720 - 725
  • [22] Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027
    Reding, Mark T.
    Pabinger, Ingrid
    Lalezari, Shadan
    Santagostino, Elena
    Mancuso, Maria Elisa
    HAEMOPHILIA, 2020, 26 (04) : E201 - E204
  • [23] Use of low-dose eloctaae∼ three times a week in prophylaxis in a volleyball player patient with severe haemophilia A
    Balci, Y. I.
    Aral, Y. Z.
    Akcan, M.
    Carti, O.
    HAEMOPHILIA, 2024, 30 : 123 - 124
  • [24] CLINICAL OUTCOMES IN NON-INHIBITOR SEVERE HAEMOPHILIA A PATIENTS RECEIVING PROPHYLAXIS ACROSS CURRENTLY AVAILABLE HAEMOPHILIA A TREATMENTS: INSIGHTS FORM THE 'COST OF HAEMOPHILIA: A SOCIOECONOMIC SURVEY III' (CHESS III) STUDY
    Blenkiron, T.
    Hinds, D.
    Santos, S.
    Burke, T.
    Grazzi, Ferri E.
    VALUE IN HEALTH, 2023, 26 (12) : S516 - S516
  • [25] Adult severe haemophilia A patients under long-term prophylaxis with factor VIII in routine clinical practice
    Mingot-Castellano, Maria E.
    Gonzalez-Diaz, Laura
    Tamayo-Bermejo, Rocio
    Heiniger-Mazo, Anabel I.
    BLOOD COAGULATION & FIBRINOLYSIS, 2015, 26 (05) : 509 - 514
  • [26] APCC (FEIBA) prophylaxis: long term experience (1998-2011) in a severe haemophilia a patient with FVIII inhibitor
    Schino, M.
    Sbrighi, P.
    Morfini, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 117 - 117
  • [27] French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy
    Meunier, S.
    Trossaert, M.
    Berger, C.
    Borel-Derlon, A.
    Dirat, G.
    Donadel-Claeyssens, S.
    Assolant, A. Durin
    Guerois, C.
    Lutz, P.
    Rafowicz, A.
    Rothschild, C.
    Chambost, H.
    ARCHIVES DE PEDIATRIE, 2009, 16 (12): : 1571 - 1578
  • [28] REAL-WORLD CLINICAL OUTCOMES IN PEOPLE FROM ACROSS EUROPE WITH SEVERE HAEMOPHILIA B RECEIVING FIX PROPHYLAXIS: AN ANALYSIS OF CHESS II
    Burke, T.
    Asghar, S.
    O'Hara, J.
    Chuang, M.
    Sawyer, E.
    Li, N. N.
    HAEMOPHILIA, 2021, 27 : 115 - 115
  • [29] LONG-TERM OUTCOMES OF PREVIOUSLY-TREATED ADULT AND ADOLESCENT PATIENTS WITH SEVERE HAEMOPHILIA A RECEIVING PROPHYLAXIS WITH EXTENDED HALF-LIFE FVIII TREATMENTS: AN ECONOMIC ANALYSIS FROM A UK PERSPECTIVE
    Benson, G.
    Morton, T.
    Thomas, H.
    Lee, X. Y.
    VALUE IN HEALTH, 2020, 23 : S696 - S696
  • [30] Retrospective 28-year long term follow-up of prophylaxis in a cohort of 49 patients with severe haemophilia A
    Oldenburg, J.
    Kraemer, L.
    Goldmann, G.
    Marquardt, N.
    Brackmann, H-H
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 133 - 133